With the global intranasal drug delivery market estimated to reach up to $71 billion over the next five years, Avance Clinical is seeing an increase in biotech clinical trials targeting this growing market demand. North America is predicted to be the largest market, with China and India the fastest growing in APAC.
Avance Clinical CEO Yvonne Lungershausen said the demand for intranasal delivery is seen across all therapeutic areas for new chemical entities as well as repurposing of currently approved medications.
“The COVID-19 era has made mucosal immunity a driver for a new generation of intranasal vaccines. Intranasal administration is becoming a preferred delivery route driven by the rise in home healthcare, self-administration, and increasing demand in the aged and pediatric care,” Lungershausen said. READ MORE HERE
